Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S561000, C548S562000
Reexamination Certificate
active
07906551
ABSTRACT:
This invention relates to 3-substituted-1,5-diaryl-2-alkyl-pyrroles of Formula I, pharmaceutical compositions containing them, and to their use for the pharmacological treatment of pain and COX-2 over-activation associated disorders. Compounds of this invention are new pyrrole derivatives bearing in position -3 of the pyrrole ring, several variously functionalized, not aliphatic, side chains which confer to the compounds a relevant COX-2 potency and selectivity along with a remarkable oral efficacy. Phenyl rings in position -1 and -5 are variously substituted, but compounds of particular interest are those substituted in position -5 with 4-methylsulphonyl-phenyl or with 4-aminosulphonyl-phenyl groups.
REFERENCES:
patent: 2 261 965 (1973-06-01), None
patent: 0323841 (1989-12-01), None
patent: 0 799 823 (1997-10-01), None
patent: 98/25896 (1998-06-01), None
Ish K. Khanna, et al, “1,2-Diarylpyrroles As Potent and Selective Inhibitors of Cyclooxygenase-2”, Journal of Medicinal Chemistry, American Chemical Society, 1997, pp. 1619-1633, vol. 40, No. 11, XP-002059990.
Mariangela Biava, et al, “1,5-Diarylpyrrole-3-Acetic Acids and Esters As Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors”, Journal of Medicinal Chemistry, Dec. 4, 2005, p. 3428-3432, vol. 48, No. 9, XP-002446244.
F. Cerreto, et al, “Studies on Anti-Candida Agents With a Pyrrole Moiety. Synthesis and Microbiological Activity of Some 3-Aminomethyl-1,5-Diaryl-2-Methyl-Pyrrole Derivatives”, European Journal Medicinal Chemistry, Oct. 1992, pp. 701-708, vol. 27, No. 7, XP-002446245.
Jean-Michel Dogn, et al. Journal of Medicinal Chemistry. Adverse Cardiovascular Effects of the Coxibs. J. Med. Chem., 2005, 48 (7), 2251-2257, 2005.
J. Scott Sawyer, et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain Bioorganic & Medicinal Chemistry Letters 14 (2004) 3581-3584.
Candida F. Pereira, et al. Induction of cyclooxygenase-2 expression during HIV-1- infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions, Journal of Leukocyte Biology, vol. 68, Sep. 2000, p. 423.
Jiuxiang Zhu. et al. From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors, Cancer Research, vol. 64, pp. 4309-4318, Jun. 15, 2004.
G.E. Leighton et al, k-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat; Br. J. Pharmacol. (1988), 93, pp. 553-560.
Giulio Maria Pasinetti, et al, Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia, Archives of Gerontology and Geriatrics 33 (2001) pp. 13-28.
Robert S. Bresalier, MD. et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial, New England Journal Medicine, 2005, vol. 352, 2005 on Feb. 15, 2005.
F. Corelli et al. Agenti Antiinfiammatori Non-Steroidei, IL Farmaco 1988(43): 251.
Rosario Sanchez-Pernaute Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease, Journal of Neuroinflammation, 2004,1:6.
Current Drug Targets—Inflammation & Allergy, vol. 4, No. 3, 2005. p. 5.
S.T. Meller et al., The possible role of Glia in Nociceptive Processing and Hyperalgesia in the Spinal Cord of the Rat. Neuoropharmacology, vol. 33 No. 11, pp. 1471-1478, 1994.
Lowell O. Randall et al. A method for measurement of analgesic activity on inflamed tissue, Arch. Int. Pharmacodyn cxl, No. 4, 1957 pp. 111 409.
Paul F. Jackson et al. Pyridinylimidazole Based p38 MAP Kinase Inhibitors, Current Topics in Medicinal Chemistry, 2002, vol. 2, pp. 1011-1020.
Hermann Stetter, Angewandte Chemie, International Edition in English, vol. 15, No. 11, 1976 pp. 639-712.
Sean D. Hurley et al, Review, Cyclooxygenase Inhibition as a Strategy to Ameliorate Brain Injury, Journal of Neurotrauma, vol. 19 No. 1, 2002.
P.N. Pompl. et al, A therapeutic role for cyclooxgenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis, Faseb J. 2003, 17 vol. 6. pp. 725.
Basilia Zingarelli, The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity, British Journal of Pharmacology (1997) vol. 120, pp. 357-366.
G Stefancich, Agenti Antiinfiammatori Non-Steroidei, II Farmaco—Ed. Sc.—vol. 39, p. 752-753, 1984.
R Koster et al, Acetic acid for analgesic screening, 1959,18,412, Supplied by The British Library.
Weiping Qin, et al. Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity, The Journal of biological chemistry 2003 By The American Society for Biochemistry and Molecular Biology. Inc, vol. 278, No. 51. pp. 50970-50977. 2003.
Anzini Maurizio
Biava Mariangela
Cappelli Andrea
Caselli Gianfranco
Giordani Antonio
Bianchi Kristin
Rottapharm S.p.A.
Saeed Kamal A
Sughrue & Mion, PLLC
LandOfFree
3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640110